Vimarsana
Biggest News Aggregation in the World

Page 2 - Interface Agency News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Interface Agency. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Interface Agency Today - Breaking & Trending Today

India's triumphs in the battle against TB - Vimarsana News

India's triumphs in the battle against TB

Authors - Dr K Madan Gopal, advisor, PHA NHSRC, Dr Suneela Garg, chair, programme advisory committee, NIHFW MoHFW, KS Uplabdh Gopal, health care professional.

DCGI grants EUA to Omicron-specific mRNA-based booster vaccine - Vimarsana News

DCGI grants EUA to Omicron-specific mRNA-based booster vaccine

The Department of Biotechnology (DBT) has announced that the Omicron-specific mRNA-based Booster vaccine developed using the indigenous platform technology by Gennova Biopharmaceuticals Ltd. and supported under the Mission COVID Suraksha, implemented by Biotechnology Industry Research Assistance Council (BIRAC), has got a nod from the office of the Drug Control General of India (DCGI) for Emergency Use Authorization (EUA).

DBT-BIRAC Supported 'Virafin' from Zydus Gets Emergency Nod For Treating Moderate COVID-19 Infections In Adults – India Education | Latest Education News India | Global Educational News - Vimarsana News

DBT-BIRAC Supported 'Virafin' from Zydus Gets Emergency Nod For Treating Moderate COVID-19 Infections In Adults – India Education | Latest Education News India | Global Educational News

New Delhi: Drug Controller General Of India (DCGI) gave a restricted emergency use approval to the Zydus Cadila’s ‘Virafin’ for treating the patients showing moderate COVID-19 symptoms. Virafin is a pegylated interferon alpha-2b(PegIFN), which when s

Department of Biotechnology provides under Mission COVID Suraksha for Gennova Biopharmaceuticals Ltd.'s novel mRNA-based COVID 19 Vaccine candidate –HGCO19. – India Education| Global Education |Education News - Vimarsana News

Department of Biotechnology provides under Mission COVID Suraksha for Gennova Biopharmaceuticals Ltd.'s novel mRNA-based COVID 19 Vaccine candidate –HGCO19. – India Education| Global Education |Education News

Share Vaccine Discovery Programme supported by the Department of Biotechnology, Govt. of India under the Mission COVID Suraksha- The Indian COVID-19 Vaccine Development Mission, implemented by BIRAC, moves into clinical trials The Department of Biotechnology (DBT), Ministry of Science & Technologyhas announced that it has approved additional funding towards clinical studies of India’s’first of its kind’ mRNA-based COVID-19 vaccine – HGCO19, developed by Pune-based biotechnology company Gennova Biopharmaceuticals Ltd. This funding has been awarded under the’Mission COVID Suraksha- Th...